Interferon alfa-2b: Difference between revisions
Content deleted Content added
m Not sure why stating facts of the production of a drug in a socialist country is "communist propaganda", whereas stating the same for Switzerland is not "capitalist propaganda"? If you disagree with the dates and specifics, sure, edit that part. But if you disagree with the statement of fact afterwards, then you oppose knowledge Pelirojopajaro |
m minor addition of accurate info |
||
| Line 39: | Line 39: | ||
| molecular_weight = |
| molecular_weight = |
||
}} |
}} |
||
'''Interferon alfa-2b''' is an antiviral or [[antineoplastic]] drug. It is a [[recombinant DNA|recombinant]] form of the protein [[IFNA2|Interferon alpha-2]] that was originally sequenced and produced recombinantly in ''[[E. coli]]''<ref>{{Cite journal|last=Nagata|first=Shigekazu|last2=Taira|first2=Hideharu|last3=Hall|first3=Alan|last4=Johnsrud|first4=Lorraine|last5=Streuli|first5=Michel|last6=Ecsödi|first6=Josef|last7=Boll|first7=Werner|last8=Cantell|first8=Kari|last9=Weissmann|first9=Charles|date=1980|title=Synthesis in E. coli of a polypeptide with human leukocyte interferon activity|url=https://www.nature.com/articles/284316a0|journal=Nature|language=en|volume=284|issue=5754|pages=316–320|doi=10.1038/284316a0|issn=1476-4687|via=}}</ref> in the laboratory of [[Charles Weissmann]] at the [[University of Zurich]].<ref>{{Citation|last=Weissmann|first=Charles|title=Recombinant interferon - the 20th anniversary|date=2001|url=https://doi.org/10.1007/978-3-0348-8346-7_1|work=Recombinant Protein Drugs|pages=3–41|editor-last=Buckel|editor-first=Peter|series=Milestones in Drug Therapy|publisher=Birkhäuser|language=en|doi=10.1007/978-3-0348-8346-7_1|isbn=978-3-0348-8346-7|access-date=2020-03-20}}</ref><ref>{{Cite journal|last=Mantei|first=Ned|last2=Schwarzstein|first2=Marco|last3=Streuli|first3=Michel|last4=Panem|first4=Sandra|last5=Nagata|first5=Shigekazu|last6=Weissmann|first6=Charles|date=1980-06-01|title=The nucleotide sequence of a cloned human leukocyte Interferon cDNA|url=http://www.sciencedirect.com/science/article/pii/0378111980901377|journal=Gene|language=en|volume=10|issue=1|pages=1–10|doi=10.1016/0378-1119(80)90137-7|issn=0378-1119}}</ref> It was developed at [[Biogen]], and ultimately marketed by Schering-Plough under the trade name '''Intron-A'''. It was also produced in 1986 in the Center for Genetic Engineering and Biotechnology of Havana, Cuba, under the name Heberon® Alfa R. |
'''Interferon alfa-2b''' is an antiviral or [[antineoplastic]] drug. It is a [[recombinant DNA|recombinant]] form of the protein [[IFNA2|Interferon alpha-2]] that was originally sequenced and produced recombinantly in ''[[E. coli]]''<ref>{{Cite journal|last=Nagata|first=Shigekazu|last2=Taira|first2=Hideharu|last3=Hall|first3=Alan|last4=Johnsrud|first4=Lorraine|last5=Streuli|first5=Michel|last6=Ecsödi|first6=Josef|last7=Boll|first7=Werner|last8=Cantell|first8=Kari|last9=Weissmann|first9=Charles|date=1980|title=Synthesis in E. coli of a polypeptide with human leukocyte interferon activity|url=https://www.nature.com/articles/284316a0|journal=Nature|language=en|volume=284|issue=5754|pages=316–320|doi=10.1038/284316a0|issn=1476-4687|via=}}</ref> in the laboratory of [[Charles Weissmann]] at the [[University of Zurich]].<ref>{{Citation|last=Weissmann|first=Charles|title=Recombinant interferon - the 20th anniversary|date=2001|url=https://doi.org/10.1007/978-3-0348-8346-7_1|work=Recombinant Protein Drugs|pages=3–41|editor-last=Buckel|editor-first=Peter|series=Milestones in Drug Therapy|publisher=Birkhäuser|language=en|doi=10.1007/978-3-0348-8346-7_1|isbn=978-3-0348-8346-7|access-date=2020-03-20}}</ref><ref>{{Cite journal|last=Mantei|first=Ned|last2=Schwarzstein|first2=Marco|last3=Streuli|first3=Michel|last4=Panem|first4=Sandra|last5=Nagata|first5=Shigekazu|last6=Weissmann|first6=Charles|date=1980-06-01|title=The nucleotide sequence of a cloned human leukocyte Interferon cDNA|url=http://www.sciencedirect.com/science/article/pii/0378111980901377|journal=Gene|language=en|volume=10|issue=1|pages=1–10|doi=10.1016/0378-1119(80)90137-7|issn=0378-1119}}</ref> It was developed at [[Biogen]], and ultimately marketed by Schering-Plough under the trade name '''Intron-A'''. It was also produced in 1986 in recombinant human form, in the Center for Genetic Engineering and Biotechnology of Havana, Cuba, under the name Heberon® Alfa R<ref>{{Cite journal|last=Nodarse-Cun�|first=Hugo|last2=L�pez-Saura|first2=Pedro A.|date=2017|title=Cuban interferon alpha-2b. Thirty years as an effective and safe drug|url=https://www.medigraphic.com/cgi-bin/new/resumenI.cgi?IDARTICULO=75882|journal=Biotecnolog�a Aplicada|language=EN|volume=34|issue=1|pages=1211–1217|issn=1027-2852}}</ref>. |
||
It has been used for a wide range of indications, including viral infections and cancers. This drug is approved around the world for the treatment of chronic [[hepatitis C]], chronic [[hepatitis B]], [[hairy cell leukemia]], [[Behçet's disease]], chronic [[myelogenous leukemia]], multiple myeloma, [[follicular lymphoma]], carcinoid tumor, [[mastocytosis]] and malignant melanoma.{{Citation needed|reason=Reliable source needed for the whole sentence|date=March 2020}} |
It has been used for a wide range of indications, including viral infections and cancers. This drug is approved around the world for the treatment of chronic [[hepatitis C]], chronic [[hepatitis B]], [[hairy cell leukemia]], [[Behçet's disease]], chronic [[myelogenous leukemia]], multiple myeloma, [[follicular lymphoma]], carcinoid tumor, [[mastocytosis]] and malignant melanoma.{{Citation needed|reason=Reliable source needed for the whole sentence|date=March 2020}} |
||
Revision as of 23:36, 7 April 2020
| Clinical data | |
|---|---|
| MedlinePlus | a690006 |
| License data | |
| Routes of administration | Subcutaneous, intramuscular |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider |
|
| ChEMBL | |
| ECHA InfoCard | 100.208.165 |
  (what is this?) (verify) | |
Interferon alfa-2b is an antiviral or antineoplastic drug. It is a recombinant form of the protein Interferon alpha-2 that was originally sequenced and produced recombinantly in E. coli[1] in the laboratory of Charles Weissmann at the University of Zurich.[2][3] It was developed at Biogen, and ultimately marketed by Schering-Plough under the trade name Intron-A. It was also produced in 1986 in recombinant human form, in the Center for Genetic Engineering and Biotechnology of Havana, Cuba, under the name Heberon® Alfa R[4].
It has been used for a wide range of indications, including viral infections and cancers. This drug is approved around the world for the treatment of chronic hepatitis C, chronic hepatitis B, hairy cell leukemia, Behçet's disease, chronic myelogenous leukemia, multiple myeloma, follicular lymphoma, carcinoid tumor, mastocytosis and malignant melanoma.[citation needed]
The medication is being used in clinical trials to treat patients with SARS-CoV-2[5] although there are no yet published results of those trials in the peer-reviewed scientific literature.
| Interferon alfa-2b products[6] | |||
|---|---|---|---|
| Product | Manufacturer | Features | Special uses |
| Alpharona | Pharmaclon | ||
| Intron-A/IntronA | Schering-Plough | ||
| Realderon | Teva | ||
| Reaferon EC | GNC Vector | ||
| Reaferon EC-Lipint | Vector-Medica | liposomal | |
| Infagel | Vector-Medica | ointment | |
| Recolin | Vector-Medica | ||
| Altevir | Bioprocess subsidiary | liquid, free of HSA | |
| Kipferon | Alfarm | combination with IgM, IgA, IgG | |
| Giaferon | A/S Vitafarma | ||
| Genferon | Biocad | ||
| Opthalamoferon | Firn-M | with dimedrol | eye infections |
See also
References
- ^ Nagata, Shigekazu; Taira, Hideharu; Hall, Alan; Johnsrud, Lorraine; Streuli, Michel; Ecsödi, Josef; Boll, Werner; Cantell, Kari; Weissmann, Charles (1980). "Synthesis in E. coli of a polypeptide with human leukocyte interferon activity". Nature. 284 (5754): 316–320. doi:10.1038/284316a0. ISSN 1476-4687.
- ^ Weissmann, Charles (2001), Buckel, Peter (ed.), "Recombinant interferon - the 20th anniversary", Recombinant Protein Drugs, Milestones in Drug Therapy, Birkhäuser, pp. 3–41, doi:10.1007/978-3-0348-8346-7_1, ISBN 978-3-0348-8346-7, retrieved 2020-03-20
- ^ Mantei, Ned; Schwarzstein, Marco; Streuli, Michel; Panem, Sandra; Nagata, Shigekazu; Weissmann, Charles (1980-06-01). "The nucleotide sequence of a cloned human leukocyte Interferon cDNA". Gene. 10 (1): 1–10. doi:10.1016/0378-1119(80)90137-7. ISSN 0378-1119.
- ^ Nodarse-Cun�, Hugo; L�pez-Saura, Pedro A. (2017). "Cuban interferon alpha-2b. Thirty years as an effective and safe drug". Biotecnolog�a Aplicada. 34 (1): 1211–1217. ISSN 1027-2852.
{{cite journal}}: replacement character in|journal=at position 12 (help); replacement character in|last2=at position 2 (help); replacement character in|last=at position 12 (help) - ^ EDT, Tom O'Connor On 3/24/20 at 5:34 PM (March 24, 2020). "Cuba uses "wonder drug" to fight coronavirus around the world despite U.S. sanctions". Newsweek.
{{cite web}}: CS1 maint: numeric names: authors list (link) - ^ Dmitrij I. Bairamashvili1 and Mikhail L. Rabinovich2* (2007). "Russia through the prism of the world biopharmaceutical market" (PDF). Biotechnol. J. 2. Archived from the original (PDF) on 2012-02-24. Retrieved 2009-06-14.
{{cite journal}}: CS1 maint: numeric names: authors list (link)
External links
Wikimedia Commons has media related to Interferon alfa-2b.
- Intron-A Summary of Product Characteristics
- Nagata S, Taira H, Hall A, et al. (Mar 1980). "Synthesis in E. coli of a polypeptide with human leukocyte interferon activity". Nature. 284 (5754): 316–20. doi:10.1038/284316a0. PMID 6987533.
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |